Nuclear Medicine and Biology
Volume 36, Issue 6 , Pages 591-603 , August 2009

Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation

  • Eftychia Koumarianou

      Affiliations

    • Institute R-RP, NCSR “Demokritos”, Athens, Hellas
    • IAE, Radioisotope Centre POLATOM, 05-400 Świerk-Otwock, Poland
    • Corresponding Author InformationCorresponding author. Institute of Radioisotopes and Radiodiagnostic Products, National Center for Scientific Research “Demokritos”, 153 10 Athens, Greece. Tel.: +30 2106503685; fax: +30 2106522661. IAE, Radioisotope Centre POLATOM, 05-400 Swierk-Otwock, Poland. Tel.: +48 227180701, fax: +48 227180350.
    • ,
  • Renata Mikołajczak

      Affiliations

    • IAE, Radioisotope Centre POLATOM, 05-400 Świerk-Otwock, Poland
    • ,
  • Dariusz Pawlak

      Affiliations

    • IAE, Radioisotope Centre POLATOM, 05-400 Świerk-Otwock, Poland
    • ,
  • Xhristos Zikos

      Affiliations

    • Institute R-RP, NCSR “Demokritos”, Athens, Hellas
    • ,
  • Pinelopi Bouziotis

      Affiliations

    • Institute R-RP, NCSR “Demokritos”, Athens, Hellas
    • ,
  • Piotr Garnuszek

      Affiliations

    • Department of Radiopharmaceuticals, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland
    • ,
  • Urszula Karczmarczyk

      Affiliations

    • Department of Radiopharmaceuticals, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland
    • ,
  • Michał Maurin

      Affiliations

    • Department of Radiopharmaceuticals, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland
    • ,
  • Spyridon C. Archimandritis

      Affiliations

    • Institute R-RP, NCSR “Demokritos”, Athens, Hellas

Received 11 March 2008 ,Revised 26 February 2009 ,Accepted 24 March 2009.

References 

  1. Radioisotopes in Medicine. In: Nuclear Issues Briefing, Paper 26. Melbourne: Uranium Information Centre Ltd; 2004;p. 1–8
  2. Prevost G, Marmant C, Gunning M, Thomas F. Therapeutic use and perspectives of synthetic peptides in oncology. Acta Oncol. 1993;32(No 2):209–215
  3. Hofland LJ, Visser-Wisselaar HA, Lamberts SW. Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. J Biochem Pharm. 1995;50(No 3):287–297
  4. Dasgupta P. Somatostatin analogues. Multiple roles in cellular proliferation, neoplasia and angiogenesis. Pharm Ther. 2004;102(Is. 1):61–85
  5. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–282
  6. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 1985;316:823–825
  7. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24(4):389–427
  8. Carney DN, Cuttitta F, Moody TW, Minna JD. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res. 1987;47:821–825
  9. Moody TW, Cuttitta F. Growth factor and peptide receptors in small cell lung cancer. Life Sci. 1993;52:1161–1173
  10. Gourni E, Paravatou M, Bouziotis P, Zikos C, Fani M, Xanthopoulos S, et al. Evaluation of a series of new 99mTc-labeled bombesin-like peptides for early cancer detection. Anticancer Res. 2006;26(1A):435–438
  11. Smith CJ, Gali H, Sieckman GL, Hayes DL, Owen NK, Mazuru DG, et al. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7–14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl Med Biol. 2003;30:101–109
  12. Heeg MJ, Jurisson SS. The role of inorganic chemistry in the development of radiometal agents for cancer therapy. Acc Chem Res. 1993;32:1050–1060
  13. Cutler CS, Smith CJ, Ehrhardt GJ, Tyler TT, Jurisson SS, Deutsch E. Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother Radiopharm. 2000;15(6):531–545
  14. Stein R, Govindan SV, Chen S, Reed L, Richel H, Griffiths GL. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of 177Lu and comparison of its efficacy with that of 90Y and residualizing 131I. J Nucl Med. 2001;42:967–974
  15. Rogers BE, Brechbiel MW, Kirkman RL, Clarkson M, Buchsbaum DJD. In:  Nicolini M editors. “In vitro binding and internalization of an Indium-111 labeled bombesin derivative to cells expressing the gastrin releasing peptide receptor.” Technetium, rhenium and other metals in chemistry and nuclear medicine. Italy: SGE Editorial; 1999;p. 519–525
  16. Kwekkeboom DJ, Bakker WH, Kooij PPM, Konijnenberg MW, Srinivasan A, Erion JL. [177Lu-DOTA0, Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;28:1319–1325
  17. Zhang H, Schumacher J, Waser B, Wild D, Eisenhut M, Reubi JC. DOTA-PESIN, a DOTA conjugate bombesin derivative designed for the treatment of bombesin receptor — positive tumours. Eur J Nucl Med Mol Imaging. 2007;34:1198–1208
  18. Cosentino U, Villa A, Pitea D, Moro G, Barone V, Maiocchi A. Conformational characterization of lanthanide(III)-DOTA complexes by ab initio investigation in vacuo and in aqueous solution. J Am Chem Soc. 2002;1,124(17):4901–4909
  19. Aime S, Botta M, Fasano M, Marques MP, Geraldes CF, Pubanz D, et al. Conformational and coordination equilibria on DOTA complexes of lanthanide metal ions in aqueous solution studied by (1)H-NMR spectroscopy. Inorg Chem. 1997;36(10):2059–2068
  20. Nock B, Nikolopoulou A, Chiotellis E, Loudos G, Maintas D, Reubi JC, et al. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med. 2003;30:247–258
  21. Li WP, Ma DS, Higginbotham C, Hoffman T, Ketring AR, Cutler CS. Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl Med Biol. 2001;28(2):145–154
  22. Toth E, Brucher E, Lazar I, Toth I. Kinetics of formation and dissociation of Lanthanide(III)-DOTA complexes. Inorg Chem. 1994;33:4070–4076
  23. Stimmel JB, Kull FC. Samarium-153 and Lutetium-177 chelation properties of selected macrocyclic and acyclic ligands. Nucl Med Biol. 1998;25:117–125
  24. Hu F, Cutler CS, Hoffman T, Sieckmen G, Volkert WA, Jurisson SS. Pm-149 DOTA bombesin analogs for potential radiotherapy. In vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-βAla-BBN(7–14)NH2. Nucl Med Biol. 2002;29:423–430
  25. Lantry LE, Cappelleti E, Maddalena ME, Fox JS, et al. 177Lu-AMBA: synthesis and characterization of a selective 177Lu-Labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med. 2006;47:1144–1152
  26. Panigone S, Nunn AD. Lutetium-177 labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy. Q J Nucl Med Mol Imaging. 2006;5(4):310–321
  27. Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC. Synthesis and evaluation of bombesin derivatives on the basis of Pan-Bombesin peptides labeled with Indium-111, Lutetium-177 and Yttrium-90 for targeting bombesin receptors-expressing tumors. Cancer Res. 2004;64:6707–6715
  28. Breeman WA, de Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabeling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003;30:917–920
  29. Schubiger PA, Alberto R, Smith A. Vehicles, chelators, and radionuclides: choosing the “building blocks” of an effective therapeutic radioimmunoconjugate. Bioconjug Chem. 1996;7:165–179
  30. Moody TW, Mantey SA, Pradhan TK, Schumann M, Nakagawa T, Martinez A. Development of high affinity camptothecin–bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells. J Biol Chem. 2004;279(22):23580–23589
  31. Zhou J, Chen J, Zhong R, Mokotoff M, Shultz LD, Ball ED. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes. Clin Cancer Res. 2006;12(7):2224–2231
  32. Moody TW, Sun LC, Mantey SA, Pradhan T, Mackey LV, Gonzales N, et al. In vitro and in vivo antitumor effects of cytotoxic camptothecin–bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. J Pharmacol Exp Ther. 2006;318(3):1265–1272
  33. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose–effect relationship. J Nucl Med. 2005;46(Suppl1):99S–106S
  34. Melis M. Dose-response effect of gelofusine on renal retention of radiolabeled octreotate in rats with CA20948 tumours. Q J Nucl Med Mol Imaging. 2008;52(2, Suppl 1):15;[19th IRIST Meeting, Krakow, Poland]
  35. Breeman WAP, Kwekkeboom DJ, Kooij PPM, Bakker WH, Hofland LJ, Visser TJ, et al. Effect on dose and specific activity on tissue distribution on indium-111-pentreotide in rats. J Nucl Med. 1995;36:623–627
  36. de Jong M, Breeman WA, Bernard BF, van Gameren A, de Bruin E, Bakker WH, et al. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med. 1999;26(7):69

PII: S0969-8051(09)00081-X

doi: 10.1016/j.nucmedbio.2009.03.006

Nuclear Medicine and Biology
Volume 36, Issue 6 , Pages 591-603 , August 2009

Article Tools

* Image Usage & Resolution